Alternatives to Immunyx Pharma

A global research-based biopharmaceutical company focused on developing advanced therapies for complex medical conditions.

Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.

AI-powered patient-centric drug simulations to accelerate and de-risk drug development.

Omnix Medical is developing a novel platform for advanced wound care management.

Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.

Biotech company developing next-generation immunotherapy agents to unlock the immune system.

Biopharmaceutical company developing human haploid stem cells for regenerative medicine and disease therapy.

Biotech developing novel technologies to restore physiological balance in apoptosis-related diseases.

Clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers.

Develops and launches Padeliporfin VTP therapy for solid tumor treatment.

Drug discovery and development company using a novel technological approach.

AI-driven digital twin of embryo development for cell-based therapies.

Developing microbiome-derived therapies to overcome resistance to immune checkpoint inhibitors in cancer treatment.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biopharmaceutical startup developing novel therapies for rare genetic diseases.

Biotech company developing a novel drug delivery platform using cell membrane-derived nanoparticles.

AI-driven platform for protein-level disease mapping and drug discovery.

Develops bacteria-based immunotherapy to enhance anti-tumor immunity for cancer treatment.

Develops a platform for adaptive clinical trial design and closed-loop execution.

Biotechnology company developing novel therapies for multiple myeloma.

Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.

Develops a platform for individual drug customization using aptamers for cancer treatment.

AI-powered insights platform for life sciences and biotech workflows.

Galimedix Therapeutics is a clinical-stage biopharmaceutical company developing novel radiopharmaceuticals for PET imaging.

Compressing biology to develop the next generation of therapies.

Developing exosome-based cancer therapeutics using AI and novel human cancer models.

Revolutionizing drug design using quantum computing, AI, and personalized medicine.

Biotechnology company developing potentially curative cell therapies for cancer patients.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Pioneering precision microbiome therapeutics for oncology using CRISPR and synthetic biology.

Developing novel therapeutics targeting the tumor microenvironment for cancer treatment.

AI platform for discovering complex multi-omics signatures for personalized medicine.

Develops autologous engineered tissue from omentum biopsies for medical conditions.

Revolutionizing prenatal testing with non-invasive fetal DNA analysis from maternal blood.

Cloud-based platform for reproducible computational research in life sciences.

Developing polymer-based nanoparticles for targeted gene therapy delivery.

Omec.ai is a life sciences startup focused on accelerating drug discovery and development through AI.

Developing novel nitroxide-based therapeutics to treat inflammatory lung diseases.

Leveraging proteomics and machine learning for improved immunotherapy decisions and drug discovery.

Developing a novel small molecule inhibitor for ovarian cancer treatment targeting DIO3.

AI-guided drug discovery platform for tissue-targeted medicines.

Biomica is developing a novel microbiome-based platform for the treatment of cancer.

OncoDecipher uses silent mutations in cancer genomes to predict cancer type and survival probability.

AI-driven drug discovery platform accelerating breakthrough scientific research.

Developing engineered biologics to harness the immune system for disease treatment.

Bio-pharmaceutical company developing novel, biologically sourced therapies for animal and human health.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Developing novel therapeutic approaches for ocular diseases.

Developing novel suprachoroidal delivery technology for targeted, rapid, and durable retinal disease treatments.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

AI-powered platform for predicting drug efficacy and safety, reducing clinical trial failures.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

Global leader in serving science, providing analytical instruments, consumables, and services for research, diagnostics, and manufacturing.